|Drug Patent Number||Company||Drug Patent Title||Drug Patent Expiry||Activity Alert|
|US6258795||WELLSTAT THERAP||Acylated uridine and cytidine and uses thereof|| |
(2 months ago)
|US7776838||WELLSTAT THERAP||Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides|| |
(3 years from now)
Vistogard is owned by Wellstat Therap.
Vistogard contains Uridine Triacetate.
Vistogard has a total of 2 drug patents out of which 1 drug patent has expired.
Expired drug patents of Vistogard are:
Vistogard was authorised for market use on 11 December, 2015.
Vistogard is available in granule;oral dosage forms.
Vistogard can be used as emergency treatment of adult & pediatric patients following fluorouracil or capecitabine overdose,or who exhibit early-onset,severe or life-threatening cardiac or cns toxicity or unusually severe adverse reactions within 96 hours.
The generics of Vistogard are possible to be released after 17 August, 2027.
|Drug Exclusivity||Drug Exclusivity Expiration|
|Orphan Drug Exclusivity (ODE)||Dec 11, 2022|
Market Authorisation Date: 11 December, 2015
Treatment: Emergency treatment of adult & pediatric patients following fluorouracil or capecitabine overdose,or who exhibit early-onset,severe or life-threatening cardiac or cns toxicity or unusually severe adve...
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic